Management of Hemorrhage in Gastrointestinal Stromal Tumors: a Review

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Apr 27

PMID 29695930

Citations 25

Authors

Qi Liu

Fanmin Kong

Jianping Zhou

Ming Dong

Qi Dong

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal stromal tumors (GISTs) are relatively common mesenchymal tumors. They originate from the wall of hollow viscera and may be found in any part of the digestive tract. The prognosis of patients with stromal tumors depends on various risk factors, including size, location, presence of mitotic figures, and tumor rupture. Emergency surgery is often required for stromal tumors with hemorrhage. The current literature suggests that stromal tumor hemorrhage indicates poor prognosis. Although the optimal treatment options for hemorrhagic GISTs are based on surgical experience, there remains controversy with regard to optimum postoperative management as well as the classification of malignant potential. This article reviews the biological characteristics, diagnostic features, prognostic factors, treatment, and postoperative management of GISTs with hemorrhage.

Citing Articles

Incidentally Discovered Duodenal Gastrointestinal Stromal Tumour (GIST): Operative Treatment and Problems After Surgery-A Case Report and Literature Review.

Luthje P, Nurmi-Luthje I Case Rep Gastrointest Med. 2025; 2025:5493240.

PMID: 39990047 PMC: 11845264. DOI: 10.1155/crgm/5493240.

Jejunal Gastrointestinal Stromal Tumor: A Rare, Elusive, and Formidable Cause of Obscure Bleeding.

Wong V, Upadhyay R, Nasir U, Friedel D Cureus. 2024; 16(10):e71286.

PMID: 39529786 PMC: 11551480. DOI: 10.7759/cureus.71286.

Duodenal gastrointestinal stromal tumor presenting with life-threatening upper GI bleeding in a young patient: A case report and literature review.

Abera S, Tadesse A, Abera K, Zegeye K, Ibrahim M, Feleke A Clin Case Rep. 2024; 12(4):e8796.

PMID: 38634092 PMC: 11022307. DOI: 10.1002/ccr3.8796.

Bleeding Gastrointestinal Stromal Tumor (GIST) Results in a Sticky Situation: The Good and Bad of Hemostatic Spray.

Syed A, Vaughan A, McCarthy J, Laczek J Cureus. 2023; 15(10):e46691.

PMID: 37942371 PMC: 10629834. DOI: 10.7759/cureus.46691.

Unusual Acute, Massive Lower Gastrointestinal Bleeding Secondary to a Proximal Jejunal Gastrointestinal Stromal Tumor: A Case Report.

Alsulaiman A, AlAli M, Essa M, Alamri O, Albdah A, Ahmad K Cureus. 2023; 15(2):e35287.

PMID: 36968934 PMC: 10037224. DOI: 10.7759/cureus.35287.

References

Martin-Broto J, Rubio L, Alemany R, Lopez-Guerrero J . Clinical implications of KIT and PDGFRA genotyping in GIST. Clin Transl Oncol. 2010; 12(10):670-6. DOI: 10.1007/s12094-010-0576-7. View

Miettinen M, Lasota J . Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438(1):1-12. DOI: 10.1007/s004280000338. View

Vadakara J, von Mehren M . Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am. 2013; 27(5):905-20. PMC: 3792495. DOI: 10.1016/j.hoc.2013.07.007. View

Kang Y, Ryu M, Yoo C, Ryoo B, Kim H, Lee J . Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1175-82. PMC: 4347867. DOI: 10.1016/S1470-2045(13)70453-4. View

Stiles Z, Rist T, Dickson P, Glazer E, Fleming M, Shibata D . Impact of body mass index on the short-term outcomes of resected gastrointestinal stromal tumors. J Surg Res. 2017; 217:123-130. DOI: 10.1016/j.jss.2017.05.010. View

DeMatteo R, Lewis J, Leung D, Mudan S, Woodruff J, Brennan M . Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231(1):51-8. PMC: 1420965. DOI: 10.1097/00000658-200001000-00008. View

Blanke C, Rankin C, Demetri G, Ryan C, von Mehren M, Benjamin R . Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008; 26(4):626-32. DOI: 10.1200/JCO.2007.13.4452. View

Tan Y, Tan L, Lu J, Huo J, Liu D . Endoscopic resection of gastric gastrointestinal stromal tumors. Transl Gastroenterol Hepatol. 2018; 2:115. PMC: 5763013. DOI: 10.21037/tgh.2017.12.03. View

DeMatteo R, Ballman K, Antonescu C, Corless C, Kolesnikova V, von Mehren M . Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013; 258(3):422-9. PMC: 4041735. DOI: 10.1097/SLA.0b013e3182a15eb7. View

10.

Blay J, Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C . Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25(9):1107-13. DOI: 10.1200/JCO.2006.09.0183. View

11.

Reichardt P, Hogendoorn P, Tamborini E, Loda M, Gronchi A, Poveda A . Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009; 36(4):290-301. DOI: 10.1053/j.seminoncol.2009.06.002. View

12.

Jiang Z, Zhang S, Peng W, Yu B . Rectal gastrointestinal stromal tumors: imaging features with clinical and pathological correlation. World J Gastroenterol. 2013; 19(20):3108-16. PMC: 3662951. DOI: 10.3748/wjg.v19.i20.3108. View

13.

Joensuu H . Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10):1411-9. DOI: 10.1016/j.humpath.2008.06.025. View

14.

Pantaleo M, Astolfi A, Indio V, Moore R, Thiessen N, Heinrich M . SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst. 2011; 103(12):983-7. DOI: 10.1093/jnci/djr130. View

15.

Zhi X, Jiang B, Yu J, Roe O, Qin J, Ni Q . Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis. Sci Rep. 2016; 6:21541. PMC: 4759596. DOI: 10.1038/srep21541. View

16.

Miettinen M, Sobin L, Lasota J . Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2004; 29(1):52-68. DOI: 10.1097/01.pas.0000146010.92933.de. View

17.

McCarter M, Antonescu C, Ballman K, Maki R, Pisters P, Demetri G . Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012; 215(1):53-9. PMC: 3383609. DOI: 10.1016/j.jamcollsurg.2012.05.008. View

18.

Lasota J, Miettinen M . Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008; 53(3):245-66. DOI: 10.1111/j.1365-2559.2008.02977.x. View

19.

Miettinen M, Majidi M, Lasota J . Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2003; 38 Suppl 5:S39-51. DOI: 10.1016/s0959-8049(02)80602-5. View

20.

Lv A, Li Z, Tian X, Guan X, Zhao M, Dong B . SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. PLoS One. 2013; 8(5):e62951. PMC: 3656858. DOI: 10.1371/journal.pone.0062951. View